Opus Genetics Inc. (IRD)
NASDAQ: IRD
· Real-Time Price · USD
1.88
0.08 (4.44%)
At close: Oct 03, 2025, 3:59 PM
4.44% (1D)
| Bid | 1.82 |
| Market Cap | 112.63M |
| Revenue (ttm) | 15.42M |
| Net Income (ttm) | -58.27M |
| EPS (ttm) | -2.05 |
| PE Ratio (ttm) | -0.92 |
| Forward PE | -4.5 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 1.92 |
| Volume | 340,613 |
| Avg. Volume (20D) | 266,576 |
| Open | 1.80 |
| Previous Close | 1.80 |
| Day's Range | 1.76 - 1.92 |
| 52-Week Range | 0.65 - 1.92 |
| Beta | 0.37 |
| Ex-Dividend Date | n/a |
Analyst Forecast
According to 0 analyst ratings, the average rating for IRD stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsOpus Genetics Inc. is scheduled to release its earnings on
Nov 11, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 months ago
+9.6%
Opus Genetics shares are trading higher after the ...
Unlock content with
Pro Subscription
9 months ago
+18.93%
Opus Genetics shares are trading higher after the company announced it secured an FDA agreement under special protocol assessment for its Phase 3 trial of Oral APX3330 in diabetic retinopathy.
